Business Wire

Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes

JANUVIA is contraindicated in patients with a history of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema. Selected important risk information about JANUVIA ...
Business Wire

TECOS, Merck’s Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes

Indications and Limitations of Use for JANUVIA® (sitagliptin) 25 mg, 50 mg and 100 mg tablets JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adults with type ...
Reuters

Novo says Victoza tops Januvia for weight loss -study

COPENHAGEN, June 26 (Reuters) - Novo Nordisk said on Saturday extension data from a study showed its new diabetes drug Victoza provided better blood sugar control and also weight reduction than ...
Renal & Urology News

New Type 2 Diabetes Indications Granted for DPP-4 Inhibitor

Merck announced that expanded labeling has been approved for Januvia (sitagliptin), the only DPP-4 inhibitor indicated domestically as an adjunct to diet and exercise to improve glycemic control in ...